Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRVGet Rating) in a research note issued to investors on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, Northland Securities downgraded shares of Nabriva Therapeutics from an “outperform” rating to an “underperform” rating in a report on Friday, January 6th.

Nabriva Therapeutics Trading Down 2.4 %

Shares of NBRV stock opened at $1.51 on Wednesday. The company has a 50 day moving average of $1.89 and a 200-day moving average of $3.61. The company has a quick ratio of 1.40, a current ratio of 2.20 and a debt-to-equity ratio of 0.02. Nabriva Therapeutics has a 12-month low of $1.22 and a 12-month high of $13.65. The firm has a market cap of $46.26 million, a P/E ratio of -0.08 and a beta of 1.67.

Nabriva Therapeutics (NASDAQ:NBRVGet Rating) last issued its quarterly earnings results on Thursday, November 10th. The biotechnology company reported ($4.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.03) by ($0.18). Nabriva Therapeutics had a negative return on equity of 120.02% and a negative net margin of 133.25%. The company had revenue of $9.15 million for the quarter, compared to analysts’ expectations of $10.68 million. Sell-side analysts anticipate that Nabriva Therapeutics will post -17.37 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC increased its holdings in Nabriva Therapeutics plc (NASDAQ:NBRVGet Rating) by 102.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 795,938 shares of the biotechnology company’s stock after buying an additional 402,144 shares during the period. Renaissance Technologies LLC owned 0.13% of Nabriva Therapeutics worth $145,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.23% of the company’s stock.

Nabriva Therapeutics Company Profile

(Get Rating)

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

Featured Articles

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.